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Background: Systemic corticosteroid may play a vital role in treating nonarteritic ischemic optic neu-
ropathy (NAION). An intravitreal route provides the advantage of avoiding systemic side effects. In this
study, we investigated the treatment result of intravitreal injection of acetonide (IVITA).
Methods: We retrospectively reviewed six patients with NAION who were treated with a single IVITA.
The patients were followed monthly for 6 months.
Results: Visual acuity improved in three patients. One patient also had a better visual ﬁeld at the 6th
month follow up. Two patients with more severe swelling of the optic disc initially did not gain better
visual acuity. One patient with a pre-existing epiretinal membrane maintained stable visual acuity.
Conclusion: Some patients with NAION may improve with IVITA treatment. Further randomized
controlled clinical trials are needed.
Copyright  2014, The Ophthalmologic Society of Taiwan. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Nonarteritic anterior ischemic optic neuropathy (NAION) affects
a large number of middle-aged patients with microvascular dis-
eases worldwide.1 To date, there is no deﬁnitive treatment for
NAION. Among the suggested treatments, systemic corticosteroid
therapy effectively improves visual acuity in some patients by faster
resolution of optic disc edema (ODE).2 A possible mechanism is via
relieving the pressure on the disc capillaries to restore some cir-
culation to the vessels of the optic nerve head.3e5 The systemic
application of corticosteroids carries the risk of systemic side ef-
fects such as worsening control of diabetes mellitus and hyper-
tension. Intravitreal injections of triamcinolone acetonide (IVITA)
can minimize systemic complications; however, only a few case
reports and case series have discussed the effects of IVITAnterests in the study.
logy, Buddhist Tzu Chi Gen-
Visual Science, Tzu Chi Uni-
, Taiwan.
ail.com (R.-K. Tsai).
ciety of Taiwan. Published by Elsetreatment in NAION. We report our experience with IVITA in six
patients with NAION.
2. Methods
We conducted a retrospective medical chart review of six pa-
tients with NAION treated by IVITA at the Buddhist Tzu Chi General
Hospital (Hualien, Taiwan) and at the KaohsiungMedical University
Hospital (Kaohsiung, Taiwan) from January 2011 to January 2013
(Table 1).
All patients experienced sudden unilateral painless visual loss
and presented with relative afferent pupillary defects and ODE. The
diagnosis of NAION was based on the typical history and clinical
presentation. Complete ophthalmic examinations were performed
and included visual acuity (measured by the Landolt chart), fundus
examination, automated visual ﬁeld examination (Humphrey 30-
2), and optical coherence tomography of macular thickness and
nerve ﬁber layer thickness. Complete blood cell count, erythrocyte
sedimentation rate, and C-reactive protein level were obtained to
exclude the arteritic type of anterior ischemic optic neuropathy and
to exclude optic neuritis. Ocular comorbidities were also assessed
to rule out pre-existing glaucoma. Triamcinolone acetonidevier Taiwan LLC. All rights reserved.
Table 2
Clinical course of the six patients with NAION after IVITA treatment.
Case Time from symptom
onset to injection
VA at injection Location of max
ODE/max thickness(mm)
VF pattern Initial VF (MD, dB) Post IVITA
Time to ODE
resolution
VA at the
6th mo
VF at the
6th mo
(MD, dB)
OCT at the
6th mo Sup
ave/Inf ave (mm)
1 4 wk 0.6 Inf/364 Inf altitudinal 18.81 4 wk 1.2 18.05 59/147
2 4 wk 0.1 Inf/398 Inf altitudinal 12.61 4 wk 0.2 12.76 63/131
3 5 wk 0.6 Inf/252 Inf altitudinal 13.54 4 wk 1.0 6.5 44/126
4 5 wk 0.04 Inf/437 (Sup max/300)* Constricted 31.42 8 wk 0.08 Loss 71/74
5 8 wk ND Inf/295 Inf altitudinal 24.37 8 wk 0.1 21.14 38/76
6 10 d 0.1 Sup/417 (Inf max/266)* Constricted 17.7 8 wk 0.01 20.91 54/65
ave ¼ average; dB ¼ decibel; Inf ¼ inferior; IVITA ¼ intravitreal injection of acetonide; max ¼ maximal; MD ¼ mean deviation; NAION ¼ nonarteritic ischemic optic neu-
ropathy; ODE ¼ optic disc edema; Sup ¼ superior; VA ¼ visual acuity; VF ¼ visual ﬁeld.
* For comparison.
Table 1
Demographic data of the six patients with NAION.
Case Age (y)/sex DM/HTN/Dyslipidemia Ocular condition in
the diseased eye
C/D ratio in
the fellow eye
Time from symptom
onset to the ﬁrst visit
Visual acuity at
the ﬁrst visit
1 57/M þ/þ/ NSþ 0.2 4 wk 0.6
2 75/M /þ/þ Macular pucker 0.2 2 wk 0.2
3 45/M /þ/ None <0.1 4 wk 0.6
4 54/M þ/þ/ None <0.1 1 wk 0.6
5 61/M þ/þ/þ None 0.1 1 wk 0.6
6 59/F /þ/ NSþ 0.2 3 d 0.1
C/D ratio ¼ cup-to-disc ratio; DM ¼ diabetes mellitus; HTN ¼ systemic hypertension; NAION ¼ nonarteritic ischemic optic neuropathy; NSþ ¼ grade 1 nuclear sclerosis.
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disturbance for 1 day before use. The superior part of the clear
suspension was removed immediately before it was injected.
Quantiﬁcation analysis by lyophilization in our laboratoryFig. 1. Serial change in Case 3. (A) The fundus initially shows upper pallor and lower hyper
visible with ﬂuorescein angiography. The mean deviation of the visual ﬁeld defect is 13.54 d
deviation of the visual ﬁeld defect is 7.88 dB. (C) At the 6th month, the mean deviation isidentiﬁed 9.7 mg of triamcinolone acetonide in one 0.05 mL in-
jection. In the operating room, after standard sterile preparation,
IVITA (0.05 mL) was administered with a 27-gauge needle 3.5 mm
from the limbus. Before and after the injection, the intraocularemic swelling. An upper ﬁlling defect and leakage from the lower swollen portion are
B. (B) One month after IVITA, the ODE has resolved and the optic disc is pale. The mean
6.5 dB.
Fig. 2. Nerve ﬁber layer thickness in Case 3. (A) Just before intravitreal injection of acetonide, the nerve ﬁber layer displays some optic disc edema. (B) Four weeks after the injection,
the optic disc edema is resolved, but the upper nerve ﬁber layer has become atrophic, which is evidence of ischemia and impingement damage.
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were examined on the ﬁrst day, and then monthly up to 6 months
after the injection. A signiﬁcant improvement in visual acuity was
deﬁned as more than three lines on the Landolt chart or from
counting ﬁngers to 0.02 or greater. An improvement in the visual
ﬁeld was deﬁned as a decrease in pre-existing scotoma by at least
7 dB in themean deviation. All patients provided informed consent.
The Institutional Review Board of the Tzu Chi General Hospital
(Hualien, Taiwan) approved the study.Table 3
Average time of ODE resolution.
Case number ODE resolution
after IVITA (wk)
ODE resolution after
symptom onset (wk)
1, 3, and 5 5.3 11
2, 4, and 6 6.7 13.5
4 and 6 8 16
IVITA ¼ intravitreal injection of acetonide; ODE ¼ optic disc edema.3. Results
All study patients completed at least 6 months of follow up
(Table 2). The time of receiving IVITA was on average 4.6 weeks
after the onset of symptoms. Three patients (Cases 1, 3, and 5) had
better visual acuity at the ﬁnal examination. Case 3 also had an
obvious improvement in the visual ﬁeld. The mean deviation
of 13.54 dB at baseline decreased to 6.5 dB at the 6th month of
follow up (Figs. 1 and 2). No signiﬁcant change in visual ﬁeld was
noted in the other patients. There were no improvements in Cases
2, 4, and 6. The latter two patients had more severe swelling of the
optic disc associated with a constricted visual ﬁeld at the time of
the IVITA. The visual status remained static before and after the
treatment in Case 2, who had a pre-existing epiretinal membrane.
The time to the resolution of ODE after IVITA in Cases 1, 3, and 5 and
in Cases 2, 4, and 6 were 5.3 weeks and 6.7 weeks, respectively, andthe time to the resolution of ODE after the onset of symptomswas a
mean of 11 weeks and 13.5 weeks, respectively (Table 3). Disc pallor
remained in all patients after the disc edema had resolved. No
patients presented with macular edema during the study. Case 4
was a steroid responder, and we used brimonidine tartrate
(Alphagan-P; Allergan, Irvine, CA, USA) to control his intraocular
pressure. No other complications were noted in this study.4. Discussion
In this study, it took less time for the ODE to resolve in the pa-
tients who beneﬁtted from the treatment. The time of ODE reso-
lutionwas longer in Cases 4 and 6, who presentedwithmore severe
swelling of their discs and a constricted visual ﬁeld at treatment
(Table 3). These two patients also subsequently developed diffuse
optic atrophy. Cases 1, 2, and 3 developed sectorial pallor optic discs
at the site opposite the previous area of maximal swelling. The
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loss due to ischemia: the more marked the ischemic damage, then
the earlier and more marked is the destruction of the axons.6 This
may be why Cases 4 and 6 did not respond well to the IVITA
treatment.
The observed resolution timewas longer in our study, compared
to previous studies. Some case reports and case series7e10 studying
IVITA in acute NAION reported that the resolution of ODE occurred
2e3 weeks after the injection. A large study3 reported that the
overall median time to spontaneous resolution of ODE from the
onset of visual loss was 7.9 weeks and that patients treated with
steroid therapy within 2 weeks after symptom onset had a signif-
icantly faster resolution of ODE, compared to untreated patients.
Most of our patients did not receive treatment at the acute stage
(i.e., within 2 weeks). However, some of them still obtained bene-
ﬁts. The role of steroids may reduce capillary permeability and
inﬂammation, thereby lessening axoplasmic ﬂow stasis and
destruction from impingement. It has been shown that cortico-
steroids can also induce tightening of endothelial barriers, thereby
contributing to a direct effect on enhancing vascular junctions at
the molecular level.11 Even if the treatment is not applied at the
acute stage and is not administered systemically, it may still work in
some NAION patients with disc edema.
Some patients in the current study had improvements in visual
acuity, which is consistent with previous studies.7,9,10 However, the
visual ﬁeld in ﬁve of our patients remained the same at the 6th
month follow up, and only Case 3 showed an improvement. The
resolution of disc edema occurred concurrently with better visual
acuity and visual ﬁeld in this patient. This surprising ﬁndingmay be
explained by this patient having fewer vascular risk factors, a
younger age, and less swelling of the nerve ﬁber layer on initial
examination. Therefore, when the impingement pressure is
released, there may be a chance for restoration of visual ﬁeld
function (Fig. 1). However, Hayreh and Zimmerman12 have shown
that visual acuity spontaneously improved in 41% of patients withNAION and it declined in 9e18% of patients. In addition, 24.5% of
patients showed a spontaneous improvement in their visual
ﬁelds.12 It is possible that the changes observed in this study were
the result of the natural history of the disease rather than as an
effect from the medication. To provide more convincing evidence,
further large-scale randomized clinical trials with a control group
are required to evaluate the effect of IVITA.References
1. Hattenhauer MG, Leavitt JA, Hodge DO, Grill R, Gray DT. Incidence of non-
arteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1997;123:103e
107.
2. Hayreh SS, Zimmerman MB. Non-arteritic anterior ischemic optic neuropathy:
role of systemic corticosteroid therapy. Graefes Arch Clin Exp Ophthalmol.
2008;246:1029e1046.
3. Hayreh SS, Zimmerman MB. Optic disc edema in non- arteritic anterior
ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol. 2007;245:1107e
1121.
4. Hayreh SS. Role of steroid therapy in nonarteritic anterior ischemic optic
neuropathy. J Neuroophthalmol. 2010;30:386e390.
5. Hayreh SS. Intravitreal triamcinolone for nonarteritic anterior ischemic optic
neuropathy. J Neuroophthalmol. 2008;28:77e78.
6. Hayreh SS. Anterior ischemic optic neuropathy V. Optic disc edema an early
sign. Arch Neurol. 1981;38:675e768.
7. Sohn BJ, Chun BY, Kwon JY. The effect of an intravitreal triamcinolone aceto-
nide injection for acute nonarteritic anterior ischemic optic neuropathy. Korean
J Ophthalmol. 2009;23:59e61.
8. Jonas JB, Spandau UH, Harder B, Sauder G. Intravitreal triamcinolone acetonide
for treatment of acute nonarteritic anterior ischemic optic neuropathy. Graefes
Arch Clin Exp Ophthalmol. 2007;245:749e750.
9. Kaderli B, Avci R, Yucel A, Guler K, Gelisken O. Intravitreal triamcinolone im-
proves recovery of visual acuity in nonarteritic anterior ischemic optic neu-
ropathy. J Neuroophthalmol. 2007;27:164e168.
10. Yaman A, Selver OB, Saatci AO, Soylev MF. Intravitreal triamcinolone acetonide
injection for acute non-arteritic anterior ischemic optic neuropathy. Clin Exp
Optom. 2008;91:561e564.
11. Duh EJ. A novel mechanism for glucocorticoid-induced tightening of endo-
thelial barriers. Invest Ophthalmol Vis Sci. 2013;54:4016.
12. Hayreh SS, Zimmerman MB. Nonarteritic anterior ischemic optic neuropathy:
natural history of visual outcome. Ophthalmology. 2008;115:298e305.
